pd 98059 has been researched along with Carcinogenesis in 5 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Notably, co-treatment of C6 glioma cells with 400 µmol/l NaHS and AOAA (an inhibitor of CBS) largely suppressed the above NaHS-induced effects." | 5.42 | Exogenous hydrogen sulfide promotes C6 glioma cell growth through activation of the p38 MAPK/ERK1/2-COX-2 pathways. ( Chen, J; Feng, J; Guo, R; He, J; Liu, C; Lu, Y; Zhang, W; Zhang, Y; Zhen, Y, 2015) |
| " The effects of ospemifene (OSP) on the immune response to a peptide cancer vaccine (PV) were evaluated after chronic [control (n = 22); OSP 50 mg/kg (n = 16); PV (n = 6); OSP+PV (n = 11)], intermittent [control (n = 10); OSP 10 and 50 mg/kg (n = 11); PV (n = 11); combination treatment (n = 11 each dose)] and pretreatment [control; OSP 100 mg/kg; PV 100 μg; combination treatment (n = 8 all groups)] ospemifene oral dosing schedules in a total of 317 mixed-sex tumor-bearing and nontumor-bearing mice." | 1.46 | Repurposing ospemifene for potentiating an antigen-specific immune response. ( DeGregorio, MW; Kao, CJ; Lin, YC; Phong, B; Vang, DP; Wurz, GT, 2017) |
| "After DEN-induced hepatocellular carcinoma (HCC) in rats showed increased phosphorylation of JNK1/2, p38, and ERK1/2, we next antagonized TGF-β1-induced phosphorylation of JNK1/2, p38, ERK1/2, Smad2/3 signaling in HepG2 cells using SP600125, SB203580, and PD98059, respectively." | 1.42 | MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells. ( Boye, A; He, S; Jiang, Y; Kan, H; Wu, C; Yang, X; Yang, Y, 2015) |
| "Notably, co-treatment of C6 glioma cells with 400 µmol/l NaHS and AOAA (an inhibitor of CBS) largely suppressed the above NaHS-induced effects." | 1.42 | Exogenous hydrogen sulfide promotes C6 glioma cell growth through activation of the p38 MAPK/ERK1/2-COX-2 pathways. ( Chen, J; Feng, J; Guo, R; He, J; Liu, C; Lu, Y; Zhang, W; Zhang, Y; Zhen, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HW | 1 |
| Huang, CY | 1 |
| Yang, SY | 1 |
| Wu, VC | 1 |
| Chu, TS | 1 |
| Chen, YM | 1 |
| Hsieh, BS | 1 |
| Wu, KD | 1 |
| Boye, A | 1 |
| Kan, H | 1 |
| Wu, C | 1 |
| Jiang, Y | 1 |
| Yang, X | 1 |
| He, S | 1 |
| Yang, Y | 1 |
| Zhen, Y | 1 |
| Zhang, W | 1 |
| Liu, C | 1 |
| He, J | 1 |
| Lu, Y | 1 |
| Guo, R | 1 |
| Feng, J | 1 |
| Zhang, Y | 1 |
| Chen, J | 1 |
| Davis, JE | 1 |
| Xie, X | 1 |
| Guo, J | 1 |
| Huang, W | 1 |
| Chu, WM | 1 |
| Huang, S | 1 |
| Teng, Y | 1 |
| Wu, G | 1 |
| Kao, CJ | 1 |
| Wurz, GT | 1 |
| Lin, YC | 1 |
| Vang, DP | 1 |
| Phong, B | 1 |
| DeGregorio, MW | 1 |
5 other studies available for pd 98059 and Carcinogenesis
| Article | Year |
|---|---|
Role of D2 dopamine receptor in adrenal cortical cell proliferation and aldosterone-producing adenoma tumorigenesis.
Topics: Adenoma; Adrenal Cortex; Adrenal Gland Neoplasms; Aldosterone; Carcinogenesis; Cell Cycle; Cell Prol | 2014 |
MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Diethylnitrosamine; Flavonoi | 2015 |
Exogenous hydrogen sulfide promotes C6 glioma cell growth through activation of the p38 MAPK/ERK1/2-COX-2 pathways.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclo | 2015 |
ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling.
Topics: ADP-Ribosylation Factor 1; Animals; Butadienes; Carcinogenesis; Cell Line, Tumor; Cell Proliferation | 2016 |
Repurposing ospemifene for potentiating an antigen-specific immune response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calmodulin; Cancer Vaccin | 2017 |